Gastric Cancer

, Volume 22, Issue 1, pp 130–137 | Cite as

Questionnaire survey on adjuvant chemotherapy for elderly patients after gastrectomy indicates their vulnelabilities

  • Toshiyuki Tanahashi
  • Kazuhiro YoshidaEmail author
  • Kazuya Yamaguchi
  • Naoki Okumura
  • Atsushi Takeno
  • Kazumasa Fujitani
  • Norimasa Fukushima
  • Nobuhiro Takiguchi
  • Yasunori Nishida
  • Narikazu Boku
  • Takaki Yoshikawa
  • Masanori Terashima
Original Article



In Japan, S-1 adjuvant chemotherapy for 1 year is the standard of care for the treatment of stage II and III patients under 80 years old with gastric cancer after curative operation. However, the feasibility of S-1 chemotherapy in patients over 80 years old has not yet been elucidated.


To clarify the current treatment situation and feasibility of S-1 treatment in patients over 80 years old, a questionnaire survey of the patients treated from January 2011 to December 2012 was conducted at 58 member institutions of the Stomach Cancer Study Group of the JCOG (Japan Clinical Oncology Group).


Gastrectomy was performed in 15,573 patients of all ages, and 1,660 (10.7%) patients were over 80 years of age. Of these elderly patients, 661 (4.2%) were diagnosed as stage II and III. While S-1 adjuvant chemotherapy was recommended to 248 (37.5%) of the stageII/III patients, only 99 (15.0%) of them actually received S-1. Interestingly, the creatinine clearance rate was between 30 and 80 mL/min in 87 (87.9%) of the patients suggesting that S-1 dose modification should be considered. Moreover, S-1 compliance was poor in patients with more than 15% body weight loss.


In general practice, surgery alone can be regarded as the standard of care for stage II and III gastric cancer patients over 80 years old. The feasibility and efficacy of S-1 adjuvant chemotherapy should be elucidated in a randomized control trial considering the vulnerabilities of the elderly.


Gastric cancer Elderly patients Adjuvant chemotherapy S-1 



The authors wish to acknowledge to all members and facilities who answered the questionnaire survey in the Stomach Cancer Study Group of the JCOG.: Aichi Cancer Center Hospital, Cancer Institute Hospital, Chiba Cancer Center, Fukuyama City Hospital, Gifu Municipal Hospital, Gifu University School of Medicine, Hakodate Goryoukaku Hospital, Hiroshima City Asa Citizens Hospital, Hiroshima City Hiroshima Citizens Hospital, Hiroshima University Hospital, Hyogo Cancer Center, Hyogo College of Medicine, Ishikawa Prefectural Central Hospital, Itami City Hospital, Iwate Medical University, Kanagawa Cancer Center, Kansai Medical University Hospital, Kansai Rosai Hospital, Keiyukai Sapporo Hospital, Kindai University Faculty of Medicine, Kitasato University School of Medicine, Kobe University School of Medicine, Miyagi Cancer Center, Nagaoka Chuo General Hospital, Nagoya University Graduate School of Medicine, National Cancer Center Hospital, National Cancer Center Hospital East, National Hospital Organization Kyoto Medical Center, Niigata Cancer Center Hospital, Oita University Hospital, Okayama University Hospital, Osaka Prefectural General Medical Center, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka Medical College, Osaka University Faculty of Medicine, Saitama Cancer Center, Saitama Medical University International Medical Center, Sakai City Medical Center, Sendai Medical Center, Shikoku Cancer Center, Shimane University Faculty of Medicine, Shizuoka Cancer Center, Shizuoka General Hospital, Tenri Hospital, Tochigi Cancer Center, Tokyo Medical and Dental University, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Toranomon Hospital, Toyama Prefectural Central Hospital, Wakayama Medical University, Yamagata Prefectural Central Hospital.

Compliance with ethical standards

Conflict of interest

K. Yoshida has received grant, personal fees and nonfinancial support from Taiho Pharm. Co., Ltd; Ono Pharm. Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Yakult Honsha Co., Ltd.; Eli Lilly Japan K.K.; Daiichi Sankyo Co., Ltd.; Merk Serono Co., Ltd.; Novartis Pharma; EA Pharma Co., Ltd.; Takeda Pharmaceutical Company; Sanofi K.K.; grant and personal fees from Johnson & Johnson K.K.; Covidien Japan; grant from Nippon Kayaku Co., Ltd.; Otsuka Pharma Co., Ltd.; Dainippon Sumitomo Pharma; personal fees from MSD K.K.; Bayer Yakuhin, Ltd. N. Takiguchi has received grant from Ministry of Health, Labor and Welfare, Japan. N. Boku has received grant and personal fees from Taiho Pharm. Co., Ltd. T. Yoshikawa has received grant from Japanese Foundation for Multidisciplinary Treatment of Cancer; grant and personal fees from Chugai Pharmaceutical Co., Ltd.; Taiho Pharm. Co., Ltd; Noartis Pharma; personal fees from Abbott Japan; Ono Pharm. Co., Ltd.; Eli Lilly Japan K.K.; Kaken Pharmaceutical; Yakult Honsha Co., Ltd.; Nippon Kayaku Co., Ltd.; Johnson & Johnson K.K.; Covidien Japan; Takeda Pharmaceutical Company; Olympus. All remaining authors declared that they have no conflict of interest.

Human rights statement and informed consent

All the questions asked in this survey were about the preference of the clinical practice of each investigator. Any patient information such as names, initials, addresses, admission dates, hospital numbers, or any other data that might identify patients were not asked or included in this survey.


  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefGoogle Scholar
  2. 2.
    Cancer Information Service NCC, Japan., Cancer Registry and Statistics. 2016.Google Scholar
  3. 3.
    The Aging Society: Current Situation and Implementation Measures FY 2013.Google Scholar
  4. 4.
    Arai H, Ouchi Y, Toba K, Endo T, Shimokado K, Tsubota K, et al. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan. Geriatr Gerontol Int. 2015;15:673–87.CrossRefGoogle Scholar
  5. 5.
    Japanese Gastric Cancer A. Japanese classification of gastric carcinoma—2nd English Edition. Gastric Cancer. 1998;1:10–24.CrossRefGoogle Scholar
  6. 6.
    Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.CrossRefGoogle Scholar
  7. 7.
    Stober J, Hong HG, Czado C, Ghosh P. Comorbidity of chronic diseases in the elderly: patterns identified by a copula design for mixed responses. Comput Stat Data Anal. 2015;88:28–39.CrossRefGoogle Scholar
  8. 8.
    Pallis AG, Fortpied C, Wedding U, Van Nes MC, Penninckx B, Ring A, et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer. 2010;46:1502–13.CrossRefGoogle Scholar
  9. 9.
    Assoc JGC. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101 – 12.CrossRefGoogle Scholar
  10. 10.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefGoogle Scholar
  11. 11.
    Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.CrossRefGoogle Scholar
  12. 12.
    Aoyama T, Yoshikawa T, Shirai J, Hayashi T, Yamada T, Tsuchida K, et al. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol. 2013;20:2000–6.CrossRefGoogle Scholar
  13. 13.
    Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.CrossRefGoogle Scholar
  14. 14.
    Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, et al. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res. 2004;24:1843–51.Google Scholar
  15. 15.
    Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37–49.CrossRefGoogle Scholar
  16. 16.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.CrossRefGoogle Scholar
  17. 17.
    Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: the mini nutritional assessment as part of the geriatric evaluation. Nutr Rev. 1996;54:S59-65.Google Scholar
  18. 18.
    Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23:2166–72.CrossRefGoogle Scholar
  19. 19.
    Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25:1824–31.CrossRefGoogle Scholar
  20. 20.
    Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat Rev. 2005;31:380–402.CrossRefGoogle Scholar
  21. 21.
    Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, et al. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer. Gastric Cancer. 2013;16:133–9.CrossRefGoogle Scholar
  22. 22.
    Tsujimoto H, Horiguchi H, Hiraki S, Yaguchi Y, Takahata R, Kumano I, et al. Tolerability of adjuvant chemotherapy with S-1 after curative resection in patients with stage II/III gastric cancer. Oncol Lett. 2012;4:1135–9.CrossRefGoogle Scholar
  23. 23.
    Takachi K, Doki Y, Ishikawa O, Miyashiro I, Sasaki Y, Ohigashi H, et al. Postoperative ghrelin levels and delayed recovery from body weight loss after distal or total gastrectomy. J Surg Res. 2006;130:1–7.CrossRefGoogle Scholar
  24. 24.
    Moertel CG, Childs DS, O’Fallon JR, Holbrook MA, Schutt AJ, Reitemeier RJ. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol. 1984;2:1249–54.CrossRefGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2018

Authors and Affiliations

  • Toshiyuki Tanahashi
    • 1
  • Kazuhiro Yoshida
    • 1
  • Kazuya Yamaguchi
    • 1
  • Naoki Okumura
    • 2
  • Atsushi Takeno
    • 3
  • Kazumasa Fujitani
    • 4
  • Norimasa Fukushima
    • 5
  • Nobuhiro Takiguchi
    • 6
  • Yasunori Nishida
    • 7
  • Narikazu Boku
    • 8
  • Takaki Yoshikawa
    • 9
  • Masanori Terashima
    • 10
  1. 1.Department of Surgical OncologyGifu University Graduate School of MedicineGifuJapan
  2. 2.Department of SurgeryGifu Municipal HospitalGifuJapan
  3. 3.Department of SurgeryKansai Rosai HospitalAmagasakiJapan
  4. 4.Department of SurgeryOsaka Prefectural General Medical CenterOsakaJapan
  5. 5.Department of SurgeryYamagata Prefectural Central HospitalYamagataJapan
  6. 6.Department of General SurgeryChiba Cancer CenterChibaJapan
  7. 7.Department of SurgeryKeiyuukai Sapporo HospitalSapporoJapan
  8. 8.Gastrointestinal Medical Oncology DivisionNational Cancer Center HospitalTokyoJapan
  9. 9.Department of Gastrointestinal SurgeryKanagawa Cancer CenterYokohamaJapan
  10. 10.Division of Gastric SurgeryShizuoka Cancer CenterSuntoJapan

Personalised recommendations